Therefore, in the pathogenesis of CKD, an SGLT2 inhibitor may reduce glucose concentrations in proximal tubular cells and the interstitial space, at least near the S1 and S2 segments, which elicit various effects on tubulointerstitial function. The gene discussed is SLC5A2; the disease is chronic kidney disease.